GLP-1 RA medications are carefully designed molecules mimicking the effects of endogenous GLP-1, but they're engineered to remain active in the body for much longer, providing sustained benefits
Cross-contamination between batches also voids any chain-of-custody documentation required for rigorous research protocols
GLP-1 agonists enhance insulin secretion from pancreatic beta cells only when blood glucose levels are elevated, a mechanism termed "glucose-dependent insulinotropic action." This physiological approach reduces the risk of hypoglycemia compared with sulfonylureas or exogenous insulin, though the risk increases when GLP-1 agents are combined with insulin or sulfonylureas, potentially requiring dose adjustments of these medications
Adhering to the discipline of this cadence may take a bit more effort but offers an alternative to the reliance on drugs
Researchers appreciate the intranasal format for its ease of use, rapid delivery, and reduced interference with digestive or hepatic processes
Sundaram K, Teng Y, Mu J, Xu Q, Xu F, Sriwastva MK, et al